AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

The European Commission has approved Tagrisso (osimertinib; AstraZeneca) combined with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced ...

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

Prior studies demonstrated osimertinib mesylate (Tagrisso, AstraZeneca) can extend survival compared with first- or second-generation EGFR TKIs.

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca) as the first adjuvant treatment for adults with early-stage non-small cell lung cancer (NSCLC) bearing ...

Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO ® (osimertinib). AstraZeneca is focused on the development of new ...

Study Overview: The clinical study titled A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed ...

Osimertinib (Tagrisso, AstraZeneca) is a third-generation EGFR-directed tyrosine kinase inhibitor. The FDA previously approved the agent for adults with advanced or metastatic EGFR-mutant NSCLC or ...

(RTTNews) - AstraZeneca's (AZN.L, AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been recommended for approval in the European Union for 1st-line ...